These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 10682270)
1. Immunohistochemical detection of lactoferrin in human astrocytomas and multiforme glioblastomas. Tuccari G; Giuffrè G; Crisafulli C; Barresi G Eur J Histochem; 1999; 43(4):317-22. PubMed ID: 10682270 [TBL] [Abstract][Full Text] [Related]
2. Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme. Arvanitis D; Malliri A; Antoniou D; Linardopoulos S; Field JK; Spandidos DA In Vivo; 1991; 5(4):317-21. PubMed ID: 1667267 [TBL] [Abstract][Full Text] [Related]
3. Annexin II marks astrocytic brain tumors of high histologic grade. Roseman BJ; Bollen A; Hsu J; Lamborn K; Israel MA Oncol Res; 1994; 6(12):561-7. PubMed ID: 7787249 [TBL] [Abstract][Full Text] [Related]
4. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078 [TBL] [Abstract][Full Text] [Related]
5. Nucleolar organizer regions (AgNORs) in astrocytic tumors. Pedal WP; Warzok RW; Hufnagl P; Roth K Zentralbl Pathol; 1994 Mar; 140(1):89-94. PubMed ID: 7515679 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Zagzag D; Miller DC; Sato Y; Rifkin DB; Burstein DE Cancer Res; 1990 Nov; 50(22):7393-8. PubMed ID: 2171762 [TBL] [Abstract][Full Text] [Related]
7. Expression of Fas/APO-1 during the progression of astrocytomas. Tachibana O; Nakazawa H; Lampe J; Watanabe K; Kleihues P; Ohgaki H Cancer Res; 1995 Dec; 55(23):5528-30. PubMed ID: 7585627 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Hsp-27 in astrocytic brain tumors: an immunohistochemical study. Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Varakis I Anticancer Res; 1997; 17(4A):2677-82. PubMed ID: 9252700 [TBL] [Abstract][Full Text] [Related]
9. [Expression of glial fibrillary acidic protein and protein S-100 in cerebral astrocytic gliomas of varying degrees of malignancy (immunohistochemical study)]. Korshunov AG; Sycheva RV Arkh Patol; 1995; 57(4):30-8. PubMed ID: 8526753 [TBL] [Abstract][Full Text] [Related]
10. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. Mikkelsen T; Yan PS; Ho KL; Sameni M; Sloane BF; Rosenblum ML J Neurosurg; 1995 Aug; 83(2):285-90. PubMed ID: 7542317 [TBL] [Abstract][Full Text] [Related]
11. Fascin expression in 90 patients with glioblastoma multiforme. Roma AA; Prayson RA Ann Diagn Pathol; 2005 Dec; 9(6):307-11. PubMed ID: 16308158 [TBL] [Abstract][Full Text] [Related]
12. Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas. Gunal A; Onguru O; Safali M; Beyzadeoglu M Neuropathology; 2008 Aug; 28(4):382-6. PubMed ID: 18298442 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor (VEGF) receptor neuropilin-1's distribution in astrocytic tumors. Broholm H; Laursen H APMIS; 2004; 112(4-5):257-63. PubMed ID: 15233640 [TBL] [Abstract][Full Text] [Related]
14. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704 [TBL] [Abstract][Full Text] [Related]
15. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424 [TBL] [Abstract][Full Text] [Related]
16. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults. Matsumoto T; Fujii T; Yabe M; Oka K; Hoshi T; Sato K Histopathology; 1998 Nov; 33(5):446-52. PubMed ID: 9839169 [TBL] [Abstract][Full Text] [Related]
17. Proteomic studies on low- and high-grade human brain astrocytomas. Odreman F; Vindigni M; Gonzales ML; Niccolini B; Candiano G; Zanotti B; Skrap M; Pizzolitto S; Stanta G; Vindigni A J Proteome Res; 2005; 4(3):698-708. PubMed ID: 15952716 [TBL] [Abstract][Full Text] [Related]
18. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Reilly KM; Loisel DA; Bronson RT; McLaughlin ME; Jacks T Nat Genet; 2000 Sep; 26(1):109-13. PubMed ID: 10973261 [TBL] [Abstract][Full Text] [Related]
19. Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion. Tsunoda K; Kitange G; Anda T; Shabani HK; Kaminogo M; Shibata S; Nagata I Brain Tumor Pathol; 2005; 22(2):79-87. PubMed ID: 18095109 [TBL] [Abstract][Full Text] [Related]
20. Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. Wharton SB; Chan KK; Whittle IR J Clin Neurosci; 2002 Mar; 9(2):165-9. PubMed ID: 11922706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]